(NASDAQ: PALI) Palisade Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.72%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.38%.
Palisade Bio's earnings in 2026 is -$24,151,000.On average, 10 Wall Street analysts forecast PALI's earnings for 2026 to be -$41,832,700, with the lowest PALI earnings forecast at -$71,445,392, and the highest PALI earnings forecast at -$32,806,558. On average, 10 Wall Street analysts forecast PALI's earnings for 2027 to be -$50,233,956, with the lowest PALI earnings forecast at -$102,064,846, and the highest PALI earnings forecast at -$32,806,558.
In 2028, PALI is forecast to generate -$62,315,102 in earnings, with the lowest earnings forecast at -$119,075,654 and the highest earnings forecast at -$45,564,663.